CD70 CAR-T cells is under clinical development by Chongqing Precision Biotech and currently in Phase I for Gynecological Cancer. According to GlobalData, Phase I drugs for Gynecological Cancer have a 74% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how CD70 CAR-T cells’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

CD70 CAR-T cells overview

Gene-modified cell therapy is under development for the treatment of CD70-positive metastatic or advanced solid tumor and CD70-positive metastatic or advanced renal cell carcinoma and gynecological cancer. It is been administered through intravenous and intraperitoneal route. The therapeutic candidate comprises of T-cells genetically modified to express chimeric antigen receptor (CAR) that acts by targeting cells expressing CD70.

For a complete picture of CD70 CAR-T cells’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.